Takeda to withdraw sNDA for lymphoma drugPharmaceutical Business ReviewTakeda Pharmaceutical and its subsidiary the Takeda Oncology company – Millennium have made decision to withdraw the supplemental new drug application (sNDA) for the use of Velcade …

Takeda Pulls FDA Application for Expanded Use of Cancer Drug VelcadeGenetic Engineering NewsMillennium: The Takeda Oncology Company has decided to withdraw its sNDA for Velcade in combination with rituximab for the treatment of relapsed follicular lymp…

iBio announces production of biosimilar rituximab drug, shares rallyProactive Investors UKiBio (AMEX:IBIO) shares rallied around 10% Wednesday after the company announced that its proprietary iBioLaunch technology has been used to produce a functional,…

Proactive Investors USA & CanadaiBio announces production of biosimilar rituximab drug, shares rallyProactive Investors USA & CanadaiBio (AMEX:IBIO) shares rallied around 10% Wednesday after the company announced that its proprietary iBioLaunch technol…

iBio Announces Production of Biosimilar Rituximab with its iBioLaunch™ TechnologySacramento BeeRituximab is a chimeric mouse-human monoclonal antibody that binds to the CD20 antigen presented on the B-cell surface. Scientists at iBio's research a…

Norfolk Eastern Daily PressUK's NICE Rebuffs Glaxo's New Lupus Drug BenlystaWall Street JournalNICE also said Benlysta should be compared with rituximab, sold by Roche Holding AG (ROG.VX), because some people with severe lupus currently receive…

Long-term data on rituximab in DLBCLOncology UpdateRituximab's efficacy with CHOP in diffuse large-B-cell lymphoma at six years has been demonstrated in a study published in the Lancet this week. The follow-up of the MInT trial was “reassuring”…